Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study)

Cassandre Gluszak, Manon de Vries-Brilland, Valérie Seegers, Céline Baroin, Helene Kieffer, Remy Delva, Delphine Cornuault-Foubert, Cassandre Gluszak, Manon de Vries-Brilland, Valérie Seegers, Céline Baroin, Helene Kieffer, Remy Delva, Delphine Cornuault-Foubert

Abstract

Background: Iron deficiency (ID) is very common in patients with solid tumors and may cause symptoms such as fatigue. However, its impact on clinical outcomes is poorly described. The aim of this prospective monocentric cohort study was to evaluate the evolution of quality of life (QoL) of these patients after iron supplementation.

Methods: We included patients treated for a solid tumor, which were diagnosed with a functional (ferritin <800 ng/mL) or absolute (ferritin <300 ng/mL) ID (transferrin saturation coefficient <20%). The primary endpoint was patients' QoL evolution between baseline and intermediate visit, 15-30 days after initial intravenous iron supplementation, assessed by the Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale. Secondary endpoints were the same assessment between baseline, intermediate, and final visit at 6 months and the evolution of functional capacities.

Results: From 02/2014 to 12/2016, 248 patients were enrolled, of whom 186 were included in the analyses, including 140/186 (75.3%) with absolute ID. Anemia was detected in 141/174 (81.0%) patients at baseline. The FACT-An scores improved significantly between inclusion and intermediate visit (P = .001) and also between the 3 times of evaluation (P < .001). The most improved dimensions were those assessing physical, emotional well-being, and fatigue. Patients who performed the functional tests in all 3 phases had a significant improvement in performance on the majority of tests.

Conclusion: The supplementation of ID was associated with an improvement of the QoL and functional capacities in patients with cancer. A randomized control trial is necessary to confirm our results. Our findings underline the importance of supportive care, including screening for ID, in oncology.

Clinical trial registration number: NCT03625661.

Keywords: FACT-An scale; anemia; cancer patients; iron deficiency; quality of life; supportive care.

© The Author(s) 2022. Published by Oxford University Press.

Figures

Figure 1.
Figure 1.
Flow chart.
Figure 2.
Figure 2.
Radar plot representing FACT-An variation from inclusion (V0; black line) to intermediate (V1; red line) and final visit (V2; green line). P-values are calculated using non-parametric Friedman test. P-value: PWB: <.001; SWB: .239; EWB: .015; FWB: .021; AnS: <.001. PWB: physical well-being; SWB: social well-being; EWB: emotional well-being; FWB: functional well-being; FACT G: Functional Assessment of Cancer Therapy-General (fatigue); AnS: anemia scale.

References

    1. Ludwig H, Van Belle S, Barrett-Lee P, et al. . The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293-2306.
    1. Kenar G, Köksoy EB, Ürün Y, Utkan G.. Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer. Support Care Cancer. 2020;28(11):5235-5242.
    1. Macciò A, Madeddu C, Gramignano G, et al. . The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica. 2015;100(1):124-132.
    1. Gilreath JA, Stenehjem DD, Rodgers GM.. Diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014;89(2):203-212.
    1. Ludwig H, Müldür E, Endler G, Hübl W.. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol. 2013;24(7):1886-1892.
    1. Saint A, Viotti J, Borchiellini D, et al. . Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study. Support Care Cancer. 2020;28(4):1639-1647.
    1. Goodnough LT, Nemeth E, Ganz T.. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010;116(23):4754-4761.
    1. Kali A, Charles MV, Seetharam RS.. Hepcidin - a novel biomarker with changing trends. Pharmacogn Rev. 2015;9(17):35-40.
    1. Houston BL, Hurrie D, Graham J, et al. . Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials. BMJ Open. 2018;8(4):e019240.
    1. von Drygalski A, Adamson JW.. Ironing out fatigue. Blood. 2011;118(12):3191-3192.
    1. Aapro M, Beguin Y, Bokemeyer C, et al. ; ESMO Guidelines Committee . Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv271.
    1. Bastit L, Vandebroek A, Altintas S, et al. . Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26(10):1611-1618.
    1. Aapro M, Österborg A, Gascón P, et al. . Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(8):1954-1962.
    1. Favrat B, Balck K, Breymann C, et al. . Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women–PREFER a randomized, placebo-controlled study. PLoS One. 2014;9(4):e94217.
    1. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl 2):13-19.
    1. Schmidt K, Vogt L, Thiel C, Jäger E, Banzer W.. Validity of the six-minute walk test in cancer patients. Int J Sports Med. 2013;34(7):631-636.
    1. Podsiadlo D, Richardson S.. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142-148.
    1. Berg K, Wood-Dauphine S, Williams Ji, Gayton D.. Measuring balance in the elderly: preliminary development of an instrument. Physiother Can. 1989;41(6):304-311.
    1. Takai Y, Ohta M, Akagi R, Kanehisa H, Kawakami Y, Fukunaga T.. Sit-to-stand test to evaluate knee extensor muscle size and strength in the elderly: a novel approach. J Physiol Anthropol. 2009;28(3):123-128.
    1. Roila F, Cortesi E.. Quality of life as a primary end point in oncology. Ann Oncol. 2001;12(Suppl 3):S3-S6.
    1. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol. 1996;14(2):671-679.
    1. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G.. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. 2011;118(12):3222-3227.
    1. Strauss WE, Auerbach M.. Health-related quality of life in patients with iron deficiency anemia: impact of treatment with intravenous iron. Patient Relat Outcome Meas. 2018;9:285-298.
    1. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr. 2001;131(2S-2):568S-579S; discussion 580S.
    1. Harrison LB, Shasha D, White C, Ramdeen B.. Radiotherapy-associated anemia: the scope of the problem. Oncologist. 2000;5(Suppl 2):1-7.
    1. Kim YT, Kim SW, Yoon BS, et al. . Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol. 2007;105(1):199-204.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться